OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer
July 27 2023 - 10:30AM
OKYO Pharma Announces Appointment of William A. Clementi as Chief
Operating Officer
OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused
bio-pharmaceutical company which is developing OK-101 to treat dry
eye disease (DED) to address the significant unmet need in this
multi-billion-dollar market, is pleased to announce that it has
appointed William A. Clementi, Pharm.D., FCP as Chief Operating
Officer. Mr Clementi will formally take up the COO role effective
September 1, 2023. Mr. Clementi's extensive experience in the
pharmaceutical industry and his achievements make him a valuable
addition to the OKYO Pharma team.
Dr. Clementi has followed a science-driven
career path since completing his NIH Training Fellowship (under
John L. McNay M.D. and Thomas M. Ludden Ph.D.) Upon completing his
Fellowship research in drug metabolism and vascular smooth muscle
relaxation, Dr. Clementi joined the University of Texas Graduate
School of Biomedical Sciences (UTGBS) faculty and the College of
Pharmacy faculty in Austin, Tx, in the Departments of Medicine and
Pharmacology at the Health Sciences Center in San Antonio. His
primary responsibilities were interdisciplinary, and he led
innovative programs in the Colleges with teaching, research, and
clinical commitments. Dr. Clementi directed the Clinical
Pharmacokinetic Consultation Service, providing novel
computer-based drug dosing to the acute care settings at two major
teaching hospitals.
Dr. Clementi continued his career in the
pharmaceutical industry, joining Synthelabo and the U.S. affiliate
Lorex Pharmaceuticals, where he held the Worldwide Director of
Market Development position. Lorex and Synthelabo launched three
EMA and FDA-approved products (betaxolol, zolpidem, and
alfuzosin).
In 1991 Dr. Clementi established a regulatory
consulting company, Clementi & Associates, Ltd. (dba as
Clementi Ltd). Clementi Ltd. provides regulatory and clinical
consultation to small companies developing drugs, biologics,
cell-based therapies, organ sustainability products and contrast
media for medical imaging. Clementi Ltd. has experience with
required regulatory submission standards and processes, including
orphan designation, exploratory INDs, expanded access INDs, and
combination drug-drug and device-drug products. Clementi Ltd also
provides high-level cGMP and GCP oversight.
Dr. Clementi is a graduate of Boston University
and the University of Texas and the College of Pharmacy.
Dr. Clementi stated “OKYO represents a unique
opportunity in the expanding biotechnology arena with a novel
product for DED. I am excited to apply my regulatory and drug
development experience and skills to OKYO and contribute to the
leadership team. I believe it will be a productive collaboration
with Dr. Jacobs to accelerate the development of OKYO’s first
product by achieving market authorization with a “first pass” NDA
approval of the lead DED indication. Topical therapies present new
challenges clinically which are best managed with strategic
interdisciplinary approaches. My interdisciplinary cross cutting
background will contribute, hopefully, to OKYO’s growth and
expanding portfolio.”
In response to the appointment, CEO Gary Jacobs expressed his
enthusiasm. "We are delighted to welcome William Clementi to OKYO
Pharma as our new Chief Operating Officer. His regulatory
knowledge, drug development experience, and commitment to
innovation align perfectly with our company's vision. As we
continue to progress our portfolio of groundbreaking therapeutics,
I am confident that Dr. Clementi's contributions will play a
pivotal role in driving OKYO Pharma's growth and success. Dr.
Clementi's appointment comes at a crucial time for OKYO Pharma,
with significant milestones on the horizon. His leadership and
operational acumen are expected to strengthen the company's
position in the pharmaceutical market and accelerate the
development and commercialization of transformative
treatments.”
About OKYOOKYO Pharma Limited (Nasdaq: OKYO) is
a life sciences company focusing on the discovery and development
of novel molecules to treat inflammatory dry eye diseases and
chronic pain. For further information, please visit
www.okyopharma.com
About OK-101OK-101 is a lipid conjugated
chemerin peptide agonist of the ChemR23 G-protein coupled receptor
which is typically found on immune cells of the eye responsible for
the inflammatory response. OK-101 was developed using a
membrane-anchored-peptide (MAP) technology to produce a novel
long-acting drug candidate for treating dry eye disease. OK-101 has
been shown to produce anti-inflammatory and pain-reducing
activities in mouse models of dry eye disease and corneal
neuropathic pain; and is designed to combat washout through the
inclusion of the lipid ‘anchor’ contained in the candidate drug
molecule to enhance the residence time of OK-101 within the ocular
environment.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.For further information, please visit the Company's
website at www.okyopharma.com
Enquiries:
OKYO Pharma Limited |
Gary S. Jacob, Chief Executive Officer |
U.S. 917-497-7560 |
|
|
|
Investor Relations |
Paul
Spencer |
+44
(0)20 7495 2379 |
|
|
|
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2024 to May 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From May 2023 to May 2024